Compare · EW vs HSCS
EW vs HSCS
Side-by-side comparison of Edwards Lifesciences Corporation (EW) and HeartSciences Inc. (HSCS): market cap, price performance, sector, and recent activity on the wire.
Summary
- Both EW and HSCS operate in Industrial Specialties (Health Care), so they compete in similar markets.
- EW is the larger of the two at $49.36B, about 5762.1x HSCS ($8.6M).
- Over the past year, EW is up 12.0% and HSCS is down 31.5% - EW leads by 43.5 points.
- HSCS has been more active in the news (16 items in the past 4 weeks vs 7 for EW).
- EW has more recent analyst coverage (25 ratings vs 0 for HSCS).
- Company
- Edwards Lifesciences Corporation
- HeartSciences Inc.
- Price
- $85.70-2.46%
- $2.85+14.00%
- Market cap
- $49.36B
- $8.6M
- 1M return
- -3.25%
- +58.33%
- 1Y return
- +12.04%
- -31.49%
- Industry
- Industrial Specialties
- Industrial Specialties
- Exchange
- NYSE
- NASDAQ
- IPO
- 2022
- News (4w)
- 7
- 16
- Recent ratings
- 25
- 0
Edwards Lifesciences Corporation
Edwards Lifesciences Corporation provides products and technologies for structural heart disease, and critical care and surgical monitoring in the United States, Europe, Japan, and internationally. It offers transcatheter heart valve replacement products for the minimally invasive replacement of heart valves; and transcatheter heart valve repair and replacement products to treat mitral and tricuspid valve diseases. The company also provides surgical heart valve therapy products, such as pericardial valves for aortic and mitral surgical valve replacement; aortic heart valves; annuloplasty rings; cardiac cannula devices; beating heart mitral valve repair system for the treatment of degenerative mitral regurgitation, as well as various procedure-enabling platforms to advance minimally invasive surgery. In addition, it offers critical care products, such as hemodynamic monitoring systems to measure a patient's heart function and fluid status in surgical and intensive care settings; pulmonary artery catheters; arterial pressure monitoring products, oximetry central venous catheters, as well as monitoring platforms that display a patient's physiological information; and Acumen Hypotension Prediction Index, which alerts clinicians in advance of a patient developing low blood pressure. The company distributes its products through a direct sales force and independent distributors. Edwards Lifesciences Corporation was founded in 1958 and is headquartered in Irvine, California.
Latest EW
- Edwards Lifesciences to Host Earnings Conference Call on July 23, 2026
- CVP, EMEACLA Bruls Annette covered exercise/tax liability with 109 shares, decreasing direct ownership by 0.53% to 20,628 units (SEC Form 4) (for withholding tax)
- CVP, Chief Financial Officer Mistras Theodora was granted 99,920 shares (SEC Form 4)
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,762 worth of shares (619 units at $91.70) as part of a pre-agreed trading plan (SEC Form 4)
- CVP, TAVR Lippis Daniel J. covered exercise/tax liability with 377 shares, decreasing direct ownership by 0.93% to 40,034 units (SEC Form 4) to cover taxes
- CVP, TAVR Lippis Daniel J. exercised 619 shares at a strike of $72.68 and sold $56,577 worth of shares (619 units at $91.40) as part of a pre-agreed trading plan (SEC Form 4)
- Edwards’ Structural Heart Leadership Demonstrated Through Expanding Body of Scientific Evidence at New York Valves
- CEO Zovighian Bernard J sold $45,982 worth of shares (523 units at $87.92) as part of a pre-agreed trading plan (SEC Form 4)
- SEC Form 11-K filed by Edwards Lifesciences Corporation
- SEC Form 11-K filed by Edwards Lifesciences Corporation
Latest HSCS
- SEC Form DEFA14A filed by HeartSciences Inc.
- HeartSciences Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits
- SEC Form 4 filed by Officer Watson Danielle
- SEC Form DEFA14A filed by HeartSciences Inc.
- HeartSciences Inc. filed SEC Form 8-K: Unregistered Sales of Equity Securities, Leadership Update, Financial Statements and Exhibits
- SEC Form DEFA14A filed by HeartSciences Inc.
- SEC Form DEFA14A filed by HeartSciences Inc.
- SEC Form DEFA14A filed by HeartSciences Inc.
- Officer Simpson Andrew was granted 425,000 shares, increasing direct ownership by 571% to 499,382 units (SEC Form 4)
- SEC Form DEFA14A filed by HeartSciences Inc.